BriaCell Therapeutics Corp's stock fell 4.94% to hit a 52-week low after the company announced a public offering priced at $5.59 per unit, aiming to raise $30 million.
Despite the positive clinical trial results showing a 100% resolution of lung metastasis in a breast cancer patient treated with Bria-OTS, the stock plummeted due to market concerns about the company's future prospects. The offering consists of 5.37 million units and is expected to close on January 15, 2026, which reflects the company's efforts to secure funding amid a challenging market environment.
The significant drop in stock price highlights investor apprehension despite the promising clinical data, indicating a potential disconnect between the company's advancements in cancer treatment and market sentiment.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
